NOVEL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, AND METHODS OF USE FOR SAME
Compounds having the following general formula, pharmaceutical compositions comprising the compounds, and methods of treating cancer, obesity, and microbial infections using such compositions: wherein: R1=H, C1-C20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, cyanomethyl, —OCH3, OC(O)CH3 or OC(O)CF3 R2=-OCH2C(O)NHNH—R5, where R5 is (a) phenyl, optionally substituted with one or more of halogen, C1-C8 alkyl, optionally substituted with halogen, —OH, —OR6, where R6 is C1-C8 alkyl, optionally substituted with halogen, or (b) 2-, 3-, or 4-pyridyl, optionally substituted with halogen, —OH, —OR6, where R6 is C1-C8 alkyl, optionally substituted with halogen, or (c) a heterocycle selected from the group consisting of imidazole, thiazole, benzimidazole, benzoxazole, benzthiazole, tetrazole, triazole, and aminothiazole; or (d) —C(O)R7, where R7 is a C1-C20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, or a heterocycle selected from the group consisting of pyridyl, imidazole, thiazole, benzimidizole, benzoxazole, benzthiazole, tetrazole, triazole, and aminothiazole; and R3 and R4, the same or different from each other, are C1-C20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl.
1 - 25 . (canceled)
26 . A compound of formula:
wherein:
R 1 is selected from the group consisting of H, C 1 -C 20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, alkylaryl, —OCH 3 , —OC(O)CH 3 and —OC(O)CF 3 ;
R 2 is —OCH 2 C(O)NHNH—R 5 , wherein R 5 is selected from the group consisting of
(a) a phenyl group, optionally substituted with one or more of a halogen or a C 1 -C 8 alkyl, which is optionally substituted with one or more of a first substitution group selected from the group consisting of a halogen, —OH, and —OR 6 , wherein R 6 is C 1 -C 8 alkyl, optionally substituted with one or more halogens;
(b) a 2-, 3-, or 4-pyridyl, optionally substituted with one or more of a second substitution group selected from the group consisting of a halogen, —OH, and —OR 6 , where R 6 is C 1 -C 8 alkyl, optionally substituted with one or more halogens;
(c) a heterocycle selected from the group consisting of imidazole, thiazole, benzimidizole, benzoxazole, benzthiazole, tetrazole, triazole, and aminothiazole; and
(d) −C(O)R 7 , where R 7 is selected from the group consisting of a C 1 -C 20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, alkylaryl, and heterocycle, which is selected from the group consisting of pyridyl, imidazole, thiazole, benzimidizole, benzoxazole, benzthiazole, tetrazole, triazole, and aminothiazole; and
R 3 and R 4 are independently selected from the group consisting of C 1 -C 20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, and alkylaryl;
with the proviso that when R 1 is —H, —OCH 3 , or —OC(O)CF 3 and R 3 is —(CH 2 ) 7 CH 3 , then R 2 is not —OCH 2 C(O)NHNH—R 5 , where R 5 is -p-C 6 H 4 Cl, —C(O)CH 3 , or
27 . A compound according to claim 26 , wherein R 1 is H.
28 . A compound according to claim 26 , wherein R 5 is selected from the group consisting of C 1 -C 10 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, and alkylaryl.
29 . A compound according to claim 26 , wherein R 3 is —H or —CH 3 .
30 . A compound according to claim 26 , wherein R 4 is n-C 6 -C 8 alkyl.
31 . A compound according to claim 26 , wherein the compound is selected from the group consisting of
32 . A pharmaceutical composition comprising a pharmaceutical diluent and a compound of formula I:
wherein:
R 1 is selected from the group consisting of H, C 1 -C 20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, alkylaryl, —OCH 3 , —OC(O)CH 3 and —OC(O)CF 3 ;
R 2 is —OCH 2 C(O)NHNH—R 5 , wherein R 5 is selected from the group consisting of
(a) a phenyl group, optionally substituted with one or more of a halogen or a C 1 -C 8 alkyl, which is optionally substituted with one or more of a first substitution group selected from the group consisting of a halogen, —OH, and —OR 6 , wherein R 6 is C 1 -C 8 alkyl, optionally substituted with one or more halogens;
(b) a 2-, 3-, or 4-pyridyl, optionally substituted with one or more of a second substitution group selected from the group consisting of a halogen, —OH, and —OR 6 , where R 6 is C 1 -C 8 alkyl, optionally substituted with one or more halogens;
(c) a heterocycle selected from the group consisting of imidazole, thiazole, benzimidizole, benzoxazole, benzthiazole, tetrazole, triazole, and aminothiazole; and
(d) —C(O)R 7 , where R 7 is selected from the group consisting of a C 1 -C 20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, alkylaryl, and heterocycle, which is selected from the group consisting of pyridyl, imidazole, thiazole, benzimidizole, benzoxazole, benzthiazole, tetrazole, triazole, and aminothiazole; and
R 3 and R 4 are independently selected from the group consisting of C 1 -C 20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, and alkylaryl;
with the proviso that when R 1 is —H, —OCH 3 , or —OC(O)CF 3 and R 3 is —(CH 2 ) 7 CH 3 , then R 2 is not —OCH 2 C(O)NHNH—R 5 , where R 5 is -p-C 6 H 4 Cl, —C(O)CH 3 , or
33 . A pharmaceutical composition according to claim 32 , wherein R 1 is H.
34 . A pharmaceutical composition according to claim 32 , wherein R 5 is selected from the group consisting of C 1 -C 10 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, and alkylaryl.
35 . A pharmaceutical composition according to claim 32 , wherein R 3 is —H or —CH 3 .
36 . A pharmaceutical composition according to claim 32 , wherein R 4 is n-C 6 -C 8 alkyl.
37 . A pharmaceutical composition according to claim 32 , wherein the compound is selected from the group consisting of:
38 . A method of treating cancer in a subject, comprising administering an effective amount of a pharmaceutical composition comprising a pharmaceutical diluent and a compound of formula I:
wherein:
R 1 is selected from the group consisting of H, C 1 -C 20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, alkylaryl, —OCH 3 , —OC(O)CH 3 and —OC(O)CF 3 ;
R 2 is —OCH 2 C(O)NHNH—R 5 , wherein R 5 is selected from the group consisting of
(a) a phenyl group, optionally substituted with one or more of a halogen or a C 1 -C 8 alkyl, which is optionally substituted with one or more of a first substitution group selected from the group consisting of a halogen, —OH, and —OR 6 , wherein R 6 is C 1 -C 8 alkyl, optionally substituted with one or more halogens;
(b) a 2-, 3-, or 4-pyridyl, optionally substituted with one or more of a second substitution group selected from the group consisting of a halogen, —OH, and —OR 6 , where R 6 is C 1 -C 8 alkyl, optionally substituted with one or more halogens;
(c) a heterocycle selected from the group consisting of imidazole, thiazole, benzimidizole, benzoxazole, benzthiazole, tetrazole, triazole, and aminothiazole; and
(d) —C(O)R 7 , where R 7 is selected from the group consisting of a C 1 -C 20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, alkylaryl, and heterocycle, which is selected from the group consisting of pyridyl, imidazole, thiazole, benzimidizole, benzoxazole, benzthiazole, tetrazole, triazole, and aminothiazole; and
R 3 and R 4 and independently selected from the group consisting of C 1 -C 20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, and alkylaryl;
with the proviso that when R 1 is —H, —OCH 3 , or —OC(O)CF 3 and R 3 is —(CH 2 ) 7 CH 3 , then R 2 is not —OCH 2 C(O)NHNH—R 5 , where R 5 is -p-C 6 H 4 Cl, —C(O)CH 3 , or
39 . The method of claim 38 , wherein the subject is a human.
40 . The method of claim 39 wherein the pharmaceutical composition comprises a compound selected from the group consisting of:
41 . The method of claim 38 , wherein the subject is an animal.
42 . The method of claim 41 , wherein the pharmaceutical composition comprises a compound selected from the group consisting of:
43 . A method of inhibiting fatty acid synthase activity in a subject comprising administering an effective amount of a pharmaceutical composition comprising a pharmaceutical diluent and a compound of formula I:
wherein:
R 1 is selected from the group consisting of H, C 1 -C 20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, alkylaryl, —OCH 3 , —OC(O)CH 3 and —OC(O)CF 3 ;
R 2 is —OCH 2 C(O)NHNH—R 5 , wherein R 5 is selected from the group consisting of
(a) a phenyl group, optionally substituted with one or more of a halogen or a C 1 -C 8 alkyl, which is optionally substituted with one or more of a first substitution group selected from the group consisting of a halogen, —OH, and —OR 6 , wherein R 6 is C 1 -C 8 alkyl, optionally substituted with one or more halogens;
(b) a 2-, 3-, or 4-pyridyl, optionally substituted with one or more of a second substitution group selected from the group consisting of a halogen, —OH, and —OR 6 , where R 6 is C 1 -C 8 alkyl, optionally substituted with one or more halogens;
(c) a heterocycle selected from the group consisting of imidazole, thiazole, benzimidizole, benzoxazole, benzthiazole, tetrazole, triazole, and aminothiazole; and
(d) —C(O)R 7 , where R 7 is selected from the group consisting of a C 1 -C 20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, alkylaryl, and heterocycle, which is selected from the group consisting of pyridyl, imidazole, thiazole, benzimidizole, benzoxazole, benzthiazole, tetrazole, triazole, and aminothiazole; and
R 3 and R 4 and independently selected from the group consisting of C 1 -C 20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, and alkylaryl;
with the proviso that when R 1 is —H, —OCH 3 , or —OC(O)CF 3 and R 3 is —(CH 2 ) 7 CH 3 , then R 2 is not —OCH 2 C(O)NHNH—R 5 , where R 5 is -p-C 6 H 4 Cl, —C(O)CH 3 , or
44 . The method of claim 43 , wherein the subject is a human.
45 . The method of claim 43 , wherein the subject is an animal.
46 . A method of inhibiting growth of invasive microbial cells in a subject comprising the administration of an effective amount of a pharmaceutical composition comprising a pharmaceutical diluent and a compound of formula I:
wherein:
R 1 is selected from the group consisting of H, C 1 -C 20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, alkylaryl, —OCH 3 , —OC(O)CH 3 and —OC(O)CF 3 ;
R 2 is —OCH 2 C(O)NHNH—R 5 , wherein R 5 is selected from the group consisting of
(a) a phenyl group, optionally substituted with one or more of a halogen or a C 1 -C 8 alkyl, which is optionally substituted with one or more of a first substitution group selected from the group consisting of a halogen, —OH, and —OR 6 , wherein R 6 is C 1 -C 8 alkyl, optionally substituted with one or more halogens;
(b) a 2-, 3-, or 4-pyridyl, optionally substituted with one or more of a second substitution group selected from the group consisting of a halogen, —OH, and —OR 6 , where R 6 is C 1 -C 8 alkyl, optionally substituted with one or more halogens;
(c) a heterocycle selected from the group consisting of imidazole, thiazole, benzimidizole, benzoxazole, benzthiazole, tetrazole, triazole, and aminothiazole; and
(d) —C(O)R 7 , where R 7 is selected from the group consisting of a C 1 -C 20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, alkylaryl, and heterocycle, which is selected from the group consisting of pyridyl, imidazole, thiazole, benzimidizole, benzoxazole, benzthiazole, tetrazole, triazole, and aminothiazole; and
R 3 and R 4 and independently selected from the group consisting of C 1 -C 20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, and alkylaryl;
with the proviso that when R 1 is —H, —OCH 3 , or —OC(O)CF 3 and R 3 is —(CH 2 ) 7 CH 3 , then R 2 is not —OCH 2 C(O)NHNH—R 5 , where R 5 is -p-C 6 H 4 Cl, —C(O)CH 3 , or
47 . The method of claim 46 , wherein the subject is a human.
48 . The method of claim 47 , wherein the compound is selected from the group consisting of:
49 . The method of claim 46 , wherein the subject is an animal.
50 . The method of claim 49 , wherein the compound is selected from the group consisting of: